title: Myeloma Is Not a Single Disease.
abstract: Treatment of plasma cell disorders has dramatically improved during the past decade as a result of the availability of new biology-based drugs, such as proteasome inhibitors and immunomodulatory agents. With increased attention to disease biology, however, it has become clear that there are many different subsets of patients with myeloma with different biologic drivers as well as different patient-based characteristics that can influence treatment. Obtaining initial genetics or genomics information can provide some of the information needed to define therapy after initial induction, and careful performance status assessment can help to define patient-specific characteristics that are important when determining the intensity of therapy. Careful assessment of both can help to optimize therapy type and duration for all patients and to improve long-term outcomes.
authors.affiliation: Emory University School of Medicine, Atlanta, GA sloni01@emory.edu.
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.affiliation: Emory University School of Medicine, Atlanta, GA.
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Nooka
mesh_terms: D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D063868:Patient Outcome Assessment; D011379:Prognosis